促红细胞生成素对小鼠和人类成纤维细胞生长因子23的影响
该研究在小鼠模型和四个独立人类CKD队列中评估促红细胞生成素(EPO)对成纤维细胞生长因子23(FGF23)的影响。小鼠内源性高EPO及外源性EPO注射均使循环总FGF23升高且不成比例地高于完整FGF23,骨髓被证明是EPO刺激FGF23产生的新来源;人类中血清EPO水平及重组人EPO剂量与总FGF23独立正相关,在680例肾移植受者中EPO与总FGF23相关而与完整FGF23无关。
要点
- EPO慢性暴露或单次给药均升高循环总FGF23,且升高幅度不成比例地高于完整FGF23。
- 骨髓是EPO刺激FGF23产生的新来源。
- 人类CKD及肾移植人群中血清EPO与重组人EPO剂量独立正相关于总FGF23。
核心结论
- EPO影响FGF23的产生与代谢,可能对CKD患者具有重要临床意义。
研究设计与样本
- 分析肾功能正常的慢性高EPO小鼠模型中慢性EPO对FGF23的影响。
- 在野生型小鼠(伴或不伴CKD)中研究外源性EPO对FGF23的影响。
- 在四个独立人类CKD队列中评估FGF23与血清EPO水平或外源性EPO剂量的关联。
- 最大队列为680例肾移植受者。
主要发现
- 高内源性EPO小鼠循环总FGF23升高,升高不成比例地高于完整FGF23,提示FGF23产生增加与蛋白水解切割增加相耦合。
- 野生型小鼠(伴或不伴CKD)单次外源性EPO剂量急性升高循环总FGF23,且不成比例地高于完整FGF23。
- 小鼠模型中骨髓被证明是EPO刺激FGF23产生的新来源。
- 人类中血清EPO水平及重组人EPO剂量与总FGF23水平在整个CKD谱及肾移植后呈独立正相关。
- 680例肾移植受者中血清EPO水平与总FGF23相关,但与完整FGF23不相关。
临床怎么用
- 肾内科医生应意识到EPO治疗可能升高总FGF23,解读FGF23结果时需区分总FGF23与完整FGF23。
- 在CKD及肾移植患者中评估FGF23时,应考虑EPO水平或剂量的潜在影响。
局限性
- 小鼠结果外推至人类需谨慎,人类数据为观察性关联,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Erythropoietin (EPO) has been reported as a novel determinant of fibroblast growth factor 23 (FGF23) production; however, it is unknown whether FGF23 is stimulated by chronic exposure to EPO or by EPO administration in nonpolycystic chronic kidney disease (CKD) models. METHODS: We analyzed the effects of chronic EPO on FGF23 in murine models with chronically high EPO levels and normal kidney function. We studied the effects of exogenous EPO on FGF23 in wild-type mice, with and without CKD, injected with EPO. Also, in four independent human CKD cohorts, we evaluated associations between FGF23 and serum EPO levels or exogenous EPO dose. RESULTS: Mice with high endogenous EPO have elevated circulating total FGF23, increased disproportionately to intact FGF23, suggesting coupling of increased FGF23 production with increased proteolytic cleavage. Similarly, in wild-type mice with and without CKD, a single exogenous EPO dose acutely increases circulating total FGF23 out of proportion to intact FGF23. In these murine models, the bone marrow is shown to be a novel source of EPO-stimulated FGF23 production. In humans, serum EPO levels and recombinant human EPO dose are positively and independently associated with total FGF23 levels across the spectrum of CKD and after kidney transplantation. In our largest cohort of 680 renal transplant recipients, serum EPO levels are associated with total FGF23, but not intact FGF23, consistent with the effects of EPO on FGF23 production and metabolism observed in our murine models. CONCLUSION: EPO affects FGF23 production and metabolism, which may have important implications for CKD patients.
引用
- Hanudel MR, Eisenga MF, Rappaport M, et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019. PMID: 30007314. doi:10.1093/ndt/gfy189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。